- About us
- UCD Clinical Trials
- Myeloma Ireland 2013
Prof J Laubach, expert in multiple myeloma, will dicuss recent advances in Multiple Myeloma management. More information on Prof Laubach and Dana Farber can be found here.Dr. Peter O'Gorman , Mater University Hospital, Dublin, Ireland
Dr. O'Gorman founder of MIRT and Consultant Haematologist will speak on the latest updates in clinical trials in Ireland and the impact they have on the patient. More information on Dr. O'Gorman and MIRT can be found here.Mary Kelly Advanced Nurse Practitioner in Haematology for Dublin & Mid Leinster Region, Ireland
Ms Kelly set up Ireland's first myeloma support group, running monthly meetings to provide advice and support to patients, families and carers.
Dr Peter O’Gorman is the current chair of the Irish blood cancer clinical trials program with the Irish Clinical Oncology Research Group (www.icorg.ie). He is the Chairman of the board of Multiple Myeloma Ireland, a new group of carers and patients/relatives affected by Multiple Myeloma. He is a founder member of, and clinical trials lead for the Myeloma Ireland Consortium, a group of blood cancer specialists focused on treating Multiple Myeloma.
Dr O’Gorman is Director of Pathology and consultant haematologist at the Mater University Hospital, an academic teaching hospital allied to University College Dublin, Dublin, Ireland. As Director of Pathology he leads and manages a staff of 130. The haematology department at the Mater has four specialist colleagues who treat a range of blood cancers.
In 2008 he established the MIRT-Ireland translational research group with Prof Ken Anderson of the Dana Farber Cancer Institute in Boston, and Prof Martin Clynes of the National Institute for Cellular Biotechnology, Dublin City University. MIRT-Ireland is taking a lead in Ireland in developing new clinical trials in Myeloma. Dr O’Gorman and Prof Anderson have developed a joint Ireland-US Myeloma Academy where doctors in training travel to Boston for research and training and then return to Ireland to benefit Irish patients with blood cancers.